Multi-omics exploration of CAV1(+) tumor epithelial subcelltype in oral squamous cell carcinoma and its impact on the immune microenvironment

口腔鳞状细胞癌中 CAV1(+) 肿瘤上皮亚细胞类型的多组学探索及其对免疫微环境的影响

阅读:1

Abstract

BACKGROUND: Oral squamous cell carcinoma originating from the gingiva and buccal mucosa (OSCC-GB) is closely associated with complex molecular mechanisms and immune evasion phenomena within the tumor microenvironment. This study aims to reveal the characteristics of tumor epithelial cell subcelltypes and their roles in tumor progression. METHODS: We organized and analyzed single-cell RNA sequencing (scRNA-seq) data from Oral squamous cell carcinoma (OSCC), categorizing tumor epithelial cells into six subcelltypes. Utilizing spatial transcriptomics, we investigated the spatial distribution of these subcelltypes. The focus was on the high malignancy tumor epithelial subcelltype, aiming to identify specific transcription factors and analyze their effects on cell status and function. Furthermore, we examined the interactions between the high malignancy tumor epithelial subcelltype and immune cells within the tumor immune microenvironment, along with the underlying mechanisms. RESULTS: Our findings indicate that the CAV1(+) epithelial subcelltype (CAV1(+)EIP) exhibits the highest copy number variation scores, significantly correlating with poor patient prognosis. Analysis of specific transcription factors reveals that high expression of LHX1 and ATF1 is associated with malignant features, while IGF2BP1, a target gene of these transcription factors, shows a negative correlation with immune regulatory pathways. Further investigations demonstrate that CAV1(+)EIP interacts with T cells through the NECTIN1-CD96 signaling network, potentially leading to immune evasion and tumor progression. CONCLUSION: This study elucidates the critical role of the CAV1(+)EIP in the development of OSCC and its interplay with the immune microenvironment. These findings provide new insights into how tumor cells evade immune surveillance and guide future immunotherapeutic strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。